



November 4, 2016

Eleven Biotherapeutics to Report Third Quarter 2016 Financial Results on November 14, 2016

-Conference call scheduled for November 14, 2016 at 8:30 a.m. ET-

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a late stage clinical oncology company advancing a broad pipeline of novel product candidates based on a Targeting Protein Therapeutics (TPTs) platform, today announced it will report third quarter 2016 financial results on Monday, November 14, 2016. Eleven's management team will host a conference call and audio webcast at 8:30 a.m. ET on Monday, November 14, 2016 to discuss the financial results and recent business developments.

To access the conference call, please dial (844) 831-3025 (domestic) or (315) 625-6887 (international) at least five minutes prior to the start time and refer to conference ID 14447038. An audio webcast of the call will also be available on the Investors & Media section of the company's website, www.elevenbio.com. An archived webcast will be available on the Company's website approximately two hours after the event and will be available for 30 days.

About Eleven Biotherapeutics

Eleven Biotherapeutics, Inc. is a late stage clinical oncology company advancing a broad pipeline of novel product candidates based upon the Company's targeted protein therapeutics (TPTs) platform. The Company's TPTs incorporate a tumor-targeting antibody fragment and a protein cytotoxic payload into a single protein molecule in order to achieve focused tumor cell killing. The TPTs fully protein construction provides enhanced linker stability and an efficient and cost effective manufacturing process. The Company believes its TPT approach offers significant advantages in treating cancer over existing antibody drug conjugate technologies. The Company believes its TPTs provide effective tumor targeting with broader cancer cell-killing properties than are achievable with small molecule payloads that require tumor cell proliferation and face multi-drug resistance mechanisms. Additionally, the Company feels their TPTs cancer cell-killing properties promote an anti-tumor immune response that will potentially combine well with immune oncology drugs such as checkpoint inhibitors. For more information please refer to the Company's website www.elevenbio.com.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20161104006046/en/>

Eleven Biotherapeutics
Leah Monteiro, 617-444-8556
Leah.monteiro@elevenbio.com

Source: Eleven Biotherapeutics, Inc.

News Provided by Acquire Media